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ABSTRACT  
Observational studies have shown a J-shaped relationship between diastolic blood pressure 
(BP) and cardiovascular events in hypertensive patients with coronary artery disease (CAD). 
We investigated whether the increased risk associated with low diastolic BP reflects elevated 
pulse pressure. In 22 672 hypertensive CAD patients from the CLARIFY registry, followed 
for a median of 5.0 years, BP was measured annually and averaged. The relationships 
between pulse pressure and diastolic BP, alone or combined, and the primary composite 
outcome (cardiovascular death or myocardial infarction) were analyzed using multivariable 
Cox proportional hazards models. Adjusted hazard ratios (HRs) for the primary outcome 
were 1.62 (95%CI 1.40–1.87), 1.00 (ref), 1.07 (0.94–1.21), 1.54 (1.32–1.79), and 2.34 (1.95–
2.81) for PP<45, 45–54 (reference), 55-64, 65–74, and ≥75 mmHg, respectively, and 1.50 
(1.31–1.72), 1.00 (reference), and 1.58 (1.42–1.77) for diastolic BPs of <70, 70–79 (ref), and 
≥80 mmHg, respectively. In a cross-classification analysis between diastolic BP and pulse 
pressure, the relationship between diastolic BP and the primary outcome remained J-shaped 
when the analysis was restricted to patients with the lowest-risk pulse pressure (45–64 
mmHg), with adjusted HRs of 1.53 (1.27–1.83), 1.00 (ref), and 1.54 (1.34–1.75) in the <70, 
70–79 (reference), and ≥80 mmHg subgroups, respectively. The J-shaped relationship 
between diastolic BP and cardiovascular events in hypertensive CAD patients persists in 
patients within the lowest-risk pulse pressure range and is therefore unlikely to be solely the 
consequence of an increased pulse pressure reflecting advanced vascular disease.  
 
Key Words: hypertension, J-curve, pulse pressure, coronary artery disease, CLARIFY 
registry 
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INTRODUCTION 
Elevated blood pressure (BP) is a well-established risk factor for cardiovascular events, and 
lowering elevated BP has been demonstrated to reduce risk.1,2 However, post-hoc analyses of 
randomized controlled trials3,4 and observational studies5,6  have shown that – in hypertensive 
patients with coronary artery disease (CAD) – the relationship between BP and 
cardiovascular events is J-shaped, particularly for diastolic BP, with an increased risk of 
cardiovascular events (except stroke) among patients with diastolic BP <70 mmHg. 
The increased cardiovascular risk observed at low diastolic BP may be a direct 
consequence of altered myocardial perfusion.6–8 However, a causal link between low diastolic 
BP and cardiovascular events has not been demonstrated in randomized controlled trials. 
Rather, such trials have shown no benefit 9,10 or a decreased risk 11 in the lowest BP groups, 
although it should be borne in mind that the mean BP in the lowest BP subgroup was never 
below the inflection point of the J-curve when considering office BP levels, either measured 
or extrapolated.12,13 Alternatively, the observed association may not be causal, but rather 
reflect reverse causality, whereby low diastolic BP would be an epiphenomenon of 
underlying poor health, itself leading to increased morbidity and mortality.14,15 Although 
indirect evidence argues against reverse causality being the sole or major explanation for the 
J-curve,5,14 irrefutable evidence will require future dedicated randomized interventional trials. 
Lastly, the association between low diastolic BP and cardiovascular events may be an 
epiphenomenon of increased pulse pressure, itself a cardiovascular risk marker,16–18 which is 
associated with diminished diastolic BP in patients with stiffened large arteries. Among 2207 
patients from a hypertension control program, Madhavan et al. reported a J-shaped relation of 
diastolic BP to myocardial infarction that occurred only among patients with a PP>63 mmHg. 
19 Similarly, Kannel et al. showed – in 7798 subjects from the Framingham study and 
offspring cohort – that the increased risk observed at low diastolic BP was confined to 
patients with increased systolic BP and, therefore, increased PP, whereas the relationship 
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between diastolic BP and outcome remained linear among patients with systolic BP<140 
mmHg. 20 More recently, Franklin et al observed in 791 individual with a previous 
cardiovascular event from the Framingham study that a diastolic BP <70 mmHg was 
associated with a greater risk than a diastolic BP of 70-79 mmHg only in patients with 
PP≥68 mmHg. 21  
The purpose of this study was to explore whether the J-curve observed for diastolic 
BP is restricted to patients with concomitant high systolic BP or PP, or whether it persists for 
patients with systolic BP and PP values within the lowest-risk range. We assessed the 
relationship between PP or diastolic BP and cardiovascular outcomes in a population of CAD 
patients treated for hypertension from the CLARIFY registry. We then performed cross-
classifications to assess the relationship between diastolic BP and outcomes, stratified by PP 
or systolic BP subgroup. 
 
METHODS 
Details of the prospective, observational, longitudinal registry of patients with stable CAD 
(CLARIFY) have been reported.5,22 Briefly, 32 703 outpatients with stable CAD were 
recruited in 45 countries between November 2009 and June 2010. Exclusion criteria were 
hospital admission for cardiovascular reasons in the past 3 months, planned revascularization, 
or any health condition compromising 5-year follow-up, including severe other 
cardiovascular diseases (e.g. advanced heart failure, severe valve disease, or history of valve 
repair or replacement). Patients received standard clinical care; enrolment did not mandate 
any specific treatment or procedure. 
Data were collected using standardized electronic case report forms at baseline and at 
every yearly visit for up to 5 years. At each yearly visit, symptoms, clinical examination, 
results of the main clinical and biological tests, treatment, and clinical outcomes were 
recorded; office BP was measured in seated subjects after a rest of 5 minutes, using the same 
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arm throughout the study, with no pre-specified device.  
This analysis was restricted to patients treated for hypertension Figure S1 in the 
Supplement), defined by “treated hypertension” on the baseline form and the use of at least 
one antihypertensive drug.  
The study was performed in accordance with the Declaration of Helsinki. Local 
ethical approval was obtained in all countries. All patients gave written informed consent. 
This study is registered with clarify-registry.com, number ISRCTN43070564. 
Blood pressure subgroups. 
Pulse pressure was calculated as the difference between systolic BP and diastolic BP. Mean 
arterial pressure was calculated as diastolic BP + 1/3 PP. Analyses were performed using the 
arithmetic mean of all BP values measured throughout follow-up, from the baseline visit to 
the visit before an event (the event depending on the outcome), or all available visits if no 
event occurred.  
For the relationship between a single BP component and outcome, patients were 
categorized into five subgroups by 10-mmHg increments, from <45 to ≥75 mmHg for PP 
(with the 45–54-mmHg subgroup as the reference), and from <60 to ≥90 mmHg for diastolic 
BP (with the 70–79-mmHg subgroup as the reference).  
For cross-classification analyses, each BP component was divided in three subgroups, 
defined from the relationship with the primary outcome, using the thresholds below and 
above which event rates increased compared to the reference group: <70, 70–79 (reference), 
and ≥80 mmHg for diastolic BP, <45, 45–64 (reference), and ≥65 mmHg for PP, and <120, 
120–139 (reference), and ≥140 mmHg for systolic BP. For systolic BP, these thresholds were 
defined from the previously established relationship between systolic BP and cardiovascular 
events in this population.5 In the cross-classification analyses, patients were further 
categorized into one of nine groups, using the combination of the three-level diastolic BP 
groupings and the three-level PP or systolic BP groupings.  
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Study outcomes.  
The primary outcome was the composite of cardiovascular death or myocardial infarction. 
Secondary outcomes included cardiovascular death, myocardial infarction, stroke, and 
hospitalization for heart failure. For patients with multiple events, the time to the first 
applicable event was considered in each analysis.  
Statistical analyses. 
Baseline characteristics are summarized according to the average PP categories prior to a 
primary outcome. Continuous variables are presented as means±standard deviations (SDs) or 
medians (interquartile ranges [IQRs]), depending on the distribution of the data; categorical 
data are presented as numbers and percentages. Comparisons between the average PP 
categories were made using either one-way analysis of variance or the Kruskal-Wallis test for 
continuous data, depending on the distribution of the data, or the chi-squared test for 
categorical data. 
Cox proportional hazards models, both adjusted and unadjusted, were used to evaluate 
the relationship between BP categories (either for a single BP component or for combined BP 
components) and outcomes.  
Covariates used for multivariable-adjustment were selected a priori as potential 
confounders and included (model 1) age, sex, geographic region, smoking status, myocardial 
infarction, percutaneous coronary intervention, coronary artery bypass grafting, diabetes, 
low- and high-density lipoprotein cholesterol levels, body mass index, glomerular filtration 
rate (GFR), peripheral artery disease, hospitalization for or symptoms of heart failure, left 
ventricular ejection fraction, ethnicity, stroke, transient ischemic attack, and baseline 
medications (aspirin, statins, angiotensin-converting enzyme inhibitors, angiotensin-receptor 
blockers, beta-blockers, calcium channel blockers, diuretics, and other antihypertensive 
medications).  
Analyses performed on PP as a single BP component were also adjusted for mean 
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arterial pressure, in a separate model. Analyses performed on diastolic BP as a single BP 
component were also adjusted for PP, in a separate model. 
No imputation was performed for missing data. Covariates with a large amount of 
missing data were categorized, including a category for missing data to minimize the loss of 
data in the analysis.  
The relationship between PP subgroups and all outcomes was further assessed after 
excluding patients with heart failure, as defined by previous hospitalization for heart failure, 
symptoms of heart failure (then excluded from covariates), or a left ventricular ejection 
fraction <45%.  
The models were further adjusted by including an interaction term between diastolic 
BP category and PP category or systolic BP category to determine whether any observed 
relationship was consistent across PP and systolic BP subgroups, respectively.  
In the event of significant interactions with diastolic BP, the relationship of diastolic 
BP and outcome was further examined in the relevant PP or systolic BP subgroups. 
Statistical analyses were performed using SAS (version 9.3). A P-value <0.05 was 
used to signify statistical significance using two-sided testing, with no correction for multiple 
comparisons.  
 
RESULTS 
Baseline characteristics of the patients in the total population (22 672 patients with CAD and 
hypertension) and by subgroups of PP are reported in Table 1 and Table S1 (baseline 
medications). Mean age was 65.2±10.0 years, 17 019 (75.1%) were men, and 7591 (33.5%) 
had diabetes. Mean systolic BP was 133.7±16.7 mmHg, mean diastolic BP was 78.2±10.1 
mmHg, and mean PP was 55.4±14.0 mmHg. Compared to patients with low PP, those with 
higher PP tended to be older, more likely to be women, have diabetes, be non-smokers, less 
likely to have had a myocardial infarction or percutaneous coronary intervention, had less 
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symptoms of heart failure, and had a higher prevalence of stroke. Baseline characteristics of 
the patients by subgroups of systolic and diastolic BP have been reported. 5  
Pulse pressure.  
After a median (IQR) follow-up of 5.0 (4.5–5.1) years, the primary outcome had occurred in 
1746 patients (7.7%). Cardiovascular death occurred in 1209 patients (5.3%), myocardial 
infarction (fatal/nonfatal) in 827 (3.6%), stroke (fatal/nonfatal) in 526 (2.3%), and hospital 
admission for heart failure in 1306 (5.8%). Event rates and adjusted hazard ratios (HRs) for 
PP subgroups are indicated in Table 2. The relationship between average PP and crude and 
adjusted risk of the primary outcome followed a J-shaped curve. A similar J-shaped 
relationship was found for cardiovascular death, myocardial infarction, stroke, and 
hospitalization for heart failure (Table 2). The increased risk for elevated PP was more 
pronounced for myocardial infarction than for the other outcomes, with progressively 
increasing HRs as average PP increased. Similar results were found after exclusion of 
patients with heart failure, except for lost and attenuated associations of elevated PP with 
stroke and hospitalization for heart failure, respectively (Table 2). 
Diastolic BP.  
As previously demonstrated for cardiovascular death, myocardial infarction, and 
hospitalization for heart failure, but not for stroke,5 the relationship between average diastolic 
BP and the primary composite outcome was J-shaped, even after multiple adjustments for 
potential confounders. A similar J-shaped pattern was seen after further adjusting for PP 
(Figure S2).  
Diastolic BP cross-classified with PP. 
Diastolic BP, categorized in the three subgroups used for cross-classifications, had similar 
relationships to cardiovascular events as when categorized in five subgroups, namely J-
shaped for all endpoints but stroke (Table S2). Event rates and HRs for the nine BP 
subgroups defined by cross-classifications between diastolic BP and PP are shown in the 
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Figure 1 (primary outcome) and Table 3 (secondary outcomes). The J-shaped relationship 
observed between diastolic BP and all endpoints but stroke remained, with very similar 
patterns, in patients with a PP within the lowest-risk range (45-64mmHg).  
Interactions between PP categories and diastolic BP categories were significant for the 
primary outcome and cardiovascular death, but non-significant for myocardial infarction, 
stroke, and hospitalization for heart failure (Table S3). Analyses by PP subgroup in case of a 
significant interaction are shown in Table S4. The significant interaction for the primary 
outcome and cardiovascular death revealed a steeper J-curve, with an even greater risk 
associated with low diastolic BP (<70 mmHg) in patients with PP<45 mmHg. Conversely, in 
patients with PP≥65 mmHg, there was no increase in the risk of cardiovascular events in 
patients with diastolic BP<70 versus 70–79 mmHg. The non-significant interaction for other 
endpoints showed that the relationship between diastolic BP and cardiovascular events was 
consistent across PP subgroups. Mean BPs in each subgroup are shown in Table S5. 
Diastolic BP cross-classified with systolic BP. 
Crude and adjusted HRs between BP subgroups, defined by cross-classifications between 
diastolic BP and systolic BP categories, are indicated in Figure 2 (primary endpoint) and 
Table 3 (secondary endpoints). The J-shaped relationship observed between diastolic BP and 
cardiovascular events remained when restricting the analysis to patients with systolic BP in 
the lowest-risk range of 120–139 mmHg. Interaction between diastolic BP and systolic BP 
was non-significant for most endpoints (Table S3), hence the relationship between diastolic 
BP and outcome was consistent across systolic BP subgroups. In the case of hospitalization 
for heart failure, there was a significant interaction between diastolic BP and systolic BP 
(p=0.0199), and the risk associated with a low diastolic BP increased as systolic BP increased 
(Table S4). Mean BP values in each subgroup are indicated in Table S5. 
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DISCUSSION 
This large international study evaluated the cardiovascular risk associated with single or 
combined components of BP in 22 672 CAD patients treated for hypertension to decipher the 
underlying mechanisms of the J-shaped relationship observed between diastolic BP and 
cardiovascular events (except stroke) in this population. Even though elevated PP was 
strongly associated with all cardiovascular endpoints, this phenomenon did not account for 
the increased risk observed at low diastolic BP. Indeed, the J-shaped relationship between 
diastolic BP and cardiovascular outcomes (primary endpoint and all secondary endpoints but 
stroke) persisted in patients with PP or systolic BP in the lowest-risk range (45–64 and 120–
139 mmHg, respectively).  
In this large population of CAD patients treated for hypertension and followed 
according to routine clinical practice, elevated PP was associated with an increased risk of all 
outcomes, even after adjustment for multiple covariates, including mean arterial pressure, 
confirming previous studies conducted in various populations that have shown that PP is an 
independent cardiovascular risk marker.16–18 PP is an indicator of left ventricle ejection 
volume and velocity, and viscoelastic properties of large arteries. Therefore, elevated PP is 
correlated with vascular ageing, both through a weakened Windkessel effect and an increased 
pulse wave velocity, with an earlier reflection wave increasing systolic BP and reducing 
diastolic BP. Furthermore, by definition, as PP increases for a given mean arterial pressure, 
systolic BP – and thus the afterload of the left ventricle – increases, and diastolic BP – and 
thus myocardial perfusion – decreases, both factors also potentially accounting for the 
increased risk associated with high PP. However, whether reducing PP reduces 
cardiovascular risk has not yet been established, unlike the clear beneficial effect of reducing 
elevated systolic BP.1,23,24  
In addition to the increased risk associated with elevated PP, we also found an 
increased risk associated with low PP (<45 mmHg). Such a J-shaped pattern for the link 
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between PP and the rate of cardiovascular events had not been shown in all previous 
studies.16,25 However, in a post-hoc analysis of the INVEST trial,18 which included 22 576 
CAD patients with hypertension, the relationship between PP and cardiovascular death and 
myocardial infarction was J-shaped, with an increased risk below a nadir value of 54 mmHg 
(95% CI, 42–60 mmHg), in line with our results. In addition, in one of the largest studies 
examining the risk associated with PP, conducted in the REACH registry (45 087 high-risk 
subjects), we recently showed that not only was elevated PP associated with multiple adverse 
cardiovascular outcomes, but patients in the first quartile of PP (<50 mmHg) also displayed 
an increased risk of cardiovascular death.17 Reverse causality, associated with low stroke 
volume,26 may at least in part explain this phenomenon. However, patients with severe aortic 
stenosis were excluded from the study, this association persisted after multiple adjustments 
for confounding factors and in a sensitivity analysis excluding patients with heart failure. 
Alternatively, the increased risk observed for low PP, which was highest in the lower end of 
the BP spectrum, may be driven by the possibly additive risks of low diastolic BP 
(compromising myocardial perfusion) combined with low mean arterial pressure 
(compromising perfusion of all other organs). Because the relationship between PP and the 
primary outcome was J-shaped in our study population, we divided PP in three subgroups for 
cross-classifications, the middle subgroup being that associated with the lowest risk (45–65 
mmHg). 
The increased risk associated with elevated PP has led many authors to hypothesize 
that the J-shaped relation to cardiovascular risk associated with diastolic BP largely reflects 
increased pulse pressure, an indicator of advanced vascular disease and stiffened large 
arteries.16,27–29 However, our results do not confirm previous studies, which had suggested 
that the increased risk associated with low diastolic BP was restricted to patients with 
increased PP19,21 or increased systolic BP.20 Importantly, these studies were conducted in 
much smaller cohorts, and did not specifically include CAD patients. We showed that, even 
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in patients within the lowest-risk range of PP or systolic BP, the J-shaped relationship 
between diastolic BP and cardiovascular events remained, which strongly argues against 
increased PP being the sole explanation for the increased risk observed at low diastolic BP. 
Similarly, the J-curve relationship between diastolic BP and the primary outcome persisted 
after adjustment for PP, as previously shown in 10001 CAD patients enrolled in the TNT 
trial.4 In line with our results, in a cohort of 331 frail elderly patients, Protogerou et al had 
found that a diastolic BP ≤60mmHg was associated with increased mortality during a two-
year follow-up, independently of large artery stiffness as measured by pulse wave analysis.30 
Not only was the J-shaped relationship between diastolic BP and cardiovascular 
events not restricted to patients with increased PP, it was actually attenuated as PP increased, 
at least for the primary outcome and cardiovascular death, for which the interaction between 
diastolic BP and PP was significant. The increased risk observed at low values of diastolic BP 
was highest when accompanied by a low PP, as discussed above. Conversely, in patients with 
elevated PP (≥65 mmHg), the risk was higher than in patients with intermediate levels of PP, 
but there was no further increase in the risk when diastolic BP was <70 mmHg. A likely 
explanation for that is that in this subgroup (PP≥65 mmHg and diastolic BP<70 mmHg), 
although the lower diastolic BP is expected to be deleterious, this may be compensated by the 
lower systolic BP accompanying these lower diastolic BP values (138 mmHg in the lowest 
diastolic BP subgroup versus 147 mmHg in the 70–79-mmHg subgroup), itself clearly 
beneficial.  
The main limitation of our study is that it is an observational registry, and we cannot 
therefore draw conclusions on whether associations between single or combined components 
of BP and cardiovascular risk are causal or would be reversed by interventions to diminish PP 
or increase low diastolic BP. Our results suggest that low myocardial perfusion may be a 
more likely explanation for the J-curve than increased vascular ageing associated with high 
PP and low diastolic BP, but do not demonstrate that it is the sole or major mechanism, nor 
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rule out some reverse causality. Assumptions based on observational studies are the basis for 
future randomized trials to define optimal BP targets. Amongst other limitations of our study, 
our results were obtained in hypertensive patients with stable CAD free from other severe 
conditions, and cannot be extrapolated to healthier hypertensive subjects, or to elderly frail 
patients. Similarly, these data should not be extrapolated to non-hypertensive CAD patients, 
who are commonly treated with BP-lowering drugs and in whom the potential deleterious 
effects of low BP remain to be studied. Finally, the CLARIFY registry reflects routine 
clinical practice, and although our results may have wider external validity than randomized 
trials, measurements of BP were less standardized and outcome identification possibly less 
accurate than in randomized trials. 
 
PERSPECTIVES 
Even though elevated PP is associated with increased cardiovascular risk and is closely 
intertwined with decreased diastolic pressure, it does not appear to be the major determinant 
of the increased risk associated with low diastolic BP in this large cohort of CAD patients. A 
compromised myocardial perfusion associated with low diastolic BP in patients with CAD 
appears to be a more plausible explanation, although reverse causation cannot be ruled out. 
Our data, although observational, suggest caution when lowering diastolic BP below 70 
mmHg, and even more so 60 mmHg, in patients with CAD treated for hypertension. 
However, only randomized trials will provide irrefutable evidence for a causal link between 
low diastolic BP and adverse cardiovascular events. BP target trials comparing levels of 
achieved BP, especially levels of diastolic BP in patients with CAD, are needed to define 
optimal BP targets in this population.  
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NOVELTY AND SIGNIFICANCE 
What is new? 
 In this large population of patients with coronary artery disease and treated 
hypertension, we show for the first time that the J-shaped relationship between 
diastolic BP and cardiovascular events persists in patients with the lowest-risk pulse 
pressure. 
What is relevant? 
 The increased risk observed at low diastolic BP is not an epiphenomenon of increased 
pulse pressure.  
 Although reverse causality cannot be ruled out by our observational study, the 
alternative hypothesis of a compromised myocardial perfusion associated with low 
diastolic BP appears to be a likely explanation for the J-curve of diastolic  
Summary 
In 22 672 hypertensive patients from the CLARIFY registry, the J-shaped relationship 
between diastolic BP and the primary outcome (cardiovascular death or myocardial 
infarction) remained in patients within the lowest-risk pulse pressure range (45-65 mmHg), 
with adjusted HRs of 1.53, 1.00, and 1.54 in the <70, 70–79 (reference), and ≥80 mmHg 
diastolic BP subgroups, respectively. 
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Figure legends  
 
FIGURE 1 Forest plots of adjusted hazard ratios for the primary outcome 
(cardiovascular death or myocardial infarction) for diastolic blood pressure subgroups 
cross-classified with pulse pressure subgroups.  
Analyses are adjusted as defined for model 1.  
HR, hazard ratio; CI, confidence interval; PP, pulse pressure; DBP, diastolic blood pressure.  
 
 
FIGURE 2 Forest Plots of Adjusted Hazard Ratios of the Primary Outcome 
(Cardiovascular Death or Myocardial Infarction) for Diastolic Blood Pressure 
Subgroups Cross-Classified with Systolic Blood Pressure Subgroups. 
Analyses are adjusted as defined for model 1.  
HR, hazard ratio; CI, confidence interval; DBP, diastolic blood pressure; SBP, systolic blood 
pressure. 
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TABLE 1 Demographic and Baseline Characteristics of the Patients, for the Total Population and Each Average On-Treatment PP 
Subgroup 
Parameter n 
Total 
population 
(n=22 672) 
Average PP categories 
p Value 
<45 mmHg 
(n=3088) 
45–54 mmHg 
(n=9013) 
55–64 mmHg 
(n=6907) 
65–74 mmHg 
(n=2611) 
≥75 mmHg 
(n=1053) 
Age, y 22 666 65.2±10.0 61.0±10.3 63.4±9.8 66.9±9.4 69.2±8.7 71.5±8.6 <0.0001 
Male 22 672 17 019 (75.1) 2505 (81.1) 6974 (77.4) 5070 (73.4) 1826 (69.9) 644 (61.2) <0.0001 
BMI, kg/m2 22 654 27.7 (25.2–30.9) 
27.2 (24.7–
30.1) 
27.8 (25.4–
30.9) 
27.8 (25.1–
31.1) 
27.8 (25.2–
31.2) 
27.6 (24.8–
30.8) <0.0001 
Diabetes 22 670 7591 (33.5) 818 (26.5) 2750 (30.5) 2461 (35.6) 1089 (41.7) 473 (44.9) <0.0001 
Smoking status 22 672 
      
<0.0001 
Current  2569 (11.3) 478 (15.5) 1100 (12.2) 683 (9.9) 234 (9.0) 74 (7.0)  
Former 
 
10 158 (44.8) 1404 (45.5) 4104 (45.5) 3044 (44.1) 1131 (43.3) 475 (45.1) 
 Never 
 
9945 (43.9) 1206 (39.1) 3809 (42.3) 3180 (46.0) 1246 (47.7) 504 (47.9) 
 PP, mmHg 22 658 55.4±14.0 40.7±7.5 50.3±8.8 59.7±10.2 68.5±12.0 82.3±14.6 – 
SBP, mmHg 22 659 133.7±16.7 118.6±11.8 129.3±12.8 137.8±14.2 145.9±16.0 158.1±18.4 – 
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Parameter n 
Total 
population 
(n=22 672) 
Average PP categories 
p Value 
<45 mmHg 
(n=3088) 
45–54 mmHg 
(n=9013) 
55–64 mmHg 
(n=6907) 
65–74 mmHg 
(n=2611) 
≥75 mmHg 
(n=1053) 
DBP, mmHg 22 659 78.2±10.1 77.9±9.2 79.0±9.6 78.1±10.2 77.4±11.4 75.8±12.1 – 
Heart rate, bpm 22 660 68.5±10.6 68.7±10.4 68.6±10.4 68.6±10.7 68.0±11.5 67.0±11.1 <0.0001 
Myocardial 
infarction 22 670 13 258 (58.5) 2081 (67.4) 5542 (61.5) 3785 (54.8) 1341 (51.4) 509 (48.3) <0.0001 
PCI 22 670 12 962 (57.2) 1863 (60.3) 5182 (57.5) 3930 (56.9) 1441 (55.2) 546 (51.9) <0.0001 
CABG 22 670 5691 (25.1) 695 (22.5) 2073 (23.0) 1804 (26.1) 770 (29.5) 349 (33.1) <0.0001 
TIA 22 670 801 (3.5) 86 (2.8) 291 (3.2) 273 (4.0) 110 (4.2) 41 (3.9) 0.0047 
Stroke 22 670 1089 (4.8) 132 (4.3) 415 (4.6) 341 (4.9) 132 (5.1) 69 (6.6) 0.035 
Hospitalization for 
HF 22 670 1211 (5.3) 202 (6.5) 445 (4.9) 343 (5.0) 158 (6.1) 63 (6.0) 0.0019 
LVEF, % 15 969 56.1±11.0 54.2±12.1 55.9±10.8 56.6±10.6 57.1±10.9 57.8±10.9 <0.0001 
HbA1C, %  6173 6.9±1.8 6.7±1.4 6.8±1.7 6.9±1.4 7.0±1.5 7.4±4.2 <0.0001 
Creatinine, µmol/L 17 165 88 (76–104) 88 (77–103) 88 (76–102) 88 (76–103) 88 (75–106) 90 (76–110) 0.0010 
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Parameter n 
Total 
population 
(n=22 672) 
Average PP categories 
p Value 
<45 mmHg 
(n=3088) 
45–54 mmHg 
(n=9013) 
55–64 mmHg 
(n=6907) 
65–74 mmHg 
(n=2611) 
≥75 mmHg 
(n=1053) 
HDL-cholesterol, 
mmol/L 16 054 1.1 (1.0–1.4) 1.1 (0.9–1.3) 1.1 (1.0–1.3) 1.2 (1.0–1.4) 1.2 (1.0–1.4) 1.1 (1.0–1.4) <0.0001 
LDL-cholesterol, 
mmol/L 15 257 2.4 (1.9–3.0) 2.3 (1.8–2.9) 2.4 (1.9–3.0) 2.4 (1.9–2.9) 2.3 (1.8–2.8) 2.4 (1.9–3.0) <0.0001 
Fasting 
triglycerides, 
mmol/L 16 806 1.4 (1.0–2.0) 1.4 (1.0–2.0) 1.5 (1.1–2.0) 1.4 (1.0–1.9) 1.4 (1.0–2.0) 1.4 (1.0–1.9) 0.0018 
Values are mean±SD, n (%), or median (IQR).  
BMI=body mass index; CABG=coronary artery bypass graft; HbA1c=hemoglobin A1c; HF=heart failure; IQR=interquartile range; LVEF=left 
ventricular ejection fraction; NYHA=New York Heart Association; PCI=percutaneous coronary intervention; PP=pulse pressure; SD=standard 
deviation; TIA=transient ischemic attack. 
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TABLE 2 Event rates and Adjusted Hazard Ratios for PP Subgroups 
 
Parameter 
HR (95% CI) for average PP subgroups 
 
p Value <45 mmHg 
45–54 
mmHg 55–64 mmHg 65–74 mmHg ≥75 mmHg 
Cardiovascular death or myocardial infarction (primary composite outcome) 
Event rate, % 9.3% 6.0% 6,8% 10,4% 16,3% <0.0001 
HR (Model 1) 1.62 (1.40–
1.87) 1.00 
1.07 (0.94–
1.21) 
1.54 (1.32–
1.79) 
2.34 (1.95–
2.81) <0.0001 
HR (Model 2) 1.62 (1.40–
1.88) 1.00 
1.07 (0.94–
1.21) 
1.54 (1.31–
1.79) 
2.33 (1.92–
2.83) <0.0001 
Excluding HF 1.63 (1.33–
2.00) 1.00 
0.99 (0.84–
1.17) 
1.38 (1.14–
1.69) 
2.15 (1.70–
2.73) <0.0001 
Cardiovascular death 
Event rate, % 7.0% 4.0% 4.6% 7.4% 11.7% <0.0001 
HR (Model 1) 1.80 (1.51–
2.13) 1.00 
1.02 (0.87–
1.19) 
1.48 (1.24–
1.78) 
2.20 (1.77–
2.74) <0.0001 
HR (Model 2) 1.79 (1.50–
2.13) 1.00 
1.02 (0.87–
1.19) 
1.49 (1.24–
1.80) 
2.23 (1.77–
2.80) <0.0001 
Excluding HF 1.90 (1.48–
2.44) 1.00 
0.94 (0.77–
1.16) 
1.40 (1.10–
1.79) 
2.04 (1.52–
2.73) <0.0001 
Myocardial infarction 
Event rate, % 3.9% 2.9% 3.4% 4.9% 7.8% <0.0001 
HR (Model 1) 1.39 (1.12–
1.73) 1.00 
1.25 (1.04–
1.50) 
1.81 (1.45–
2.25) 
2.94 (2.25–
3.83) <0.0001 
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HR (Model 2) 1.42 (1.14–
1.78) 1.00 
1.23 (1.02–
1.47) 
1.74 (1.39–
2.20) 
2.79 (2.10–
3.69) <0.0001 
Excluding HF 1.41 (1.06–
1.88) 1.00 
1.18 (0.95–
1.48) 
1.55 (1.18–
2.04) 
2.32 (1.65–
3.25) <0.0001 
Stroke 
Event rate, % 2.1% 1.9% 2.2% 3.3% 4.4% <0.0001 
HR (Model 1) 1.26 (0.94–
1.68) 1.00 
1.06 (0.85–
1.32) 
1.56 (1.20–
2.04) 
1.98 (1.41–
2.80) 0.0001 
HR (Model 2) 1.39 (1.04–
1.86) 1.00 
0.98 (0.78–
1.23) 
1.35 (1.03–
1.79) 
1.56 (1.09–
2.25) 0.0044 
Excluding HF 1.55 (1.09–
2.21) 1.00 
0.78 (0.59–
1.03) 
1.06 (0.76–
1.49) 
1.24 (0.81–
1.91) 0.0032 
Hospitalization for HF 
Event rate, % 7.7% 5.3% 5.4% 6.5% 8.6% <0.0001 
HR (Model 1) 1.47 (1.25–
1.73) 1.00 
1.17 (1.02–
1.35) 
1.40 (1.16–
1.68) 
2.08 (1.63–
2.65) <0.0001 
HR (Model 2) 1.56 (1.32–
1.83) 1.00 
1.12 (0.97–
1.29) 
1.27 (1.05–
1.54) 
1.82 (1.41–
2.35) <0.0001 
Excluding HF 1.51 (1.11–
2.06) 1.00 
0.98 (0.78–
1.25) 
0.92 (0.66–
1.29) 
1.65 (1.13–
2.41) 0.0019 
 
Model 1, see methods. Model 2: additional adjustment for mean arterial pressure. 
CI=confidence interval; GFR=glomerular filtration rate; HF=heart failure; HR=hazard ratio; 
PP=pulse pressure.
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TABLE 3 Cross-Classifications Analysis: Event Rates and adjusted Hazard Ratios for Secondary Outcomes  
  
  
PP 
Diastolic BP subgroups Systolic 
BP 
Diastolic BP subgroups 
<70 mmHg 70–79 mmHg ≥80 mmHg <70 mmHg 70–79 mmHg ≥80 mmHg 
Cardiovascular death 
n/N 
<45 
mmHg 
50/332 84/1509 81/1230 
<120 
mmHg 
121/1073 93/1472 13/148 
Event rate, % 15.1 5.6 6.6 11.3 6.3 8.8 
HR (95% CI) 
3.49 (2.56–
4.77) 
1.64 (1.27–
2.10) 
2.80 (2.17–
3.61) 
2.51 (2.02–
3.14) 
1.77 (1.39, 
2.26) 
4.08 (2.32, 
7.15) 
n/N 
45–64 
mmHg 
126/1807 278/7805 275/6318 
120–139 
mmHg 
105/1671 270/7826 218/5101 
Event rate, % 7.0 3.6 4.4 6.3 3.5 4.3 
HR (95% CI) 
1.55 (1.25–
1.93) 1.00 (–) 
1.52 (1.28–
1.81) 
1.43 (1.14–
1.81) 1.00 (–) 
1.59 (1.32–
1.91) 
n/N 
≥65 
mmHg 
81/913 113/1581 120/1144 
≥140 
mmHg 
31/308 112/1597 245/3443 
Event rate, % 8.9 7.1 10.5 10.1 7.0 7.1 
HR (95% CI) 
1.77 (1.37–
2.29) 
1.67 (1.34–
2.09) 
3.10 (2.49–
3.84) 
1.85 (1.26–
2.71) 
1.72 (1.37–
2.14) 
2.43 (2.04–
2.90) 
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PP 
Diastolic BP subgroups Systolic 
BP 
Diastolic BP subgroups 
<70 mmHg 70–79 mmHg ≥80 mmHg <70 mmHg 70–79 mmHg ≥80 mmHg 
myocardial infarction               
n/N 
<45 
mmHg 
23/338 49/1504 49/1242 
<120 
mmHg 
61/1075 48/1464 6/149 
Event rate, % 6.8 3.3 3.9 5.7 3.3 4.0 
HR (95% CI) 
2.75 (1.77–
4.27) 
1.37 (0.99–
1.88) 
1.91 (1.38–
2.64) 
2.06 (1.54–
2.77) 
1.28 (0.93–
1.76) 
2.13 (0.94–
4.83) 
n/N 
45–64 
mmHg 
76/1803 185/7755 234/6341 
120–139 
mmHg 
74/1665 195/7783 162/5108 
Event rate, % 4.2 2.4 3.7 4.4 2.5 3.2 
HR (95% CI) 
1.61 (1.23–
2.12) 1.00 (–) 
1.68 (1.38–
2.05) 
1.62 (1.23–
2.14) 1.00 (–) 
1.38 (1.12–
1.71) 
n/N 
≥65 
mmHg 
49/905 77/1577 84/1174 
≥140 
mmHg 
13/306 68/1589 199/3500 
Event rate, % 5.4 4.9 7.2 4.2 4.3 5.7 
HR (95% CI) 
2.07 (1.49–
2.87) 
2.03 (1.55–
2.66) 
3.46 (2.66–
4.49) 
1.41 (0.80–
2.50) 
1.69 (1.28–
2.23) 
2.60 (2.12–
3.18) 
stroke 
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PP 
Diastolic BP subgroups Systolic 
BP 
Diastolic BP subgroups 
<70 mmHg 70–79 mmHg ≥80 mmHg <70 mmHg 70–79 mmHg ≥80 mmHg 
n/N 
<45 
mmHg 
11/339 25/1508 29/1245 
<120 
mmHg 
26/1076 26/1469 1/147 
Event rate, % 3.2 1.7 2.3 2.4 1.8 0.7 
HR (95% CI) 
2.17 (1.16–
4.05) 
1.22 (0.79–
1.89) 
2.10 (1.39–
3.18) 
1.38 (0.90–
2.11) 
1.19 (0.78–
1.82) 
0.67 (0.09–
4.83) 
n/N 
45–64 
mmHg 
43/1804 127/7761 157/6327 
120–139 
mmHg 
46/1669 131/7789 108/5109 
Event rate, % 2.4 1.6 2.5 2.8 1.7 2.1 
HR (95% CI) 
1.32 (0.93–
1.87) 1.00 (–) 
1.77 (1.39–
2.26) 
1.42 (1.01–
2.01) 1.00 (–) 
1.53 (1.17–
1.98) 
n/N 
≥65 
mmHg 
31/912 55/1588 47/1155 
≥140 
mmHg 
13/310 50/1599 124/3471 
Event rate, % 3.4 3.5 4.1 4.2 3.1 3.6 
HR (95% CI) 
1.66 (1.11–
2.49) 
1.93 (1.40–
2.66) 
2.82 (2.01–
3.95) 
1.80 (1.01–
3.22) 
1.74 (1.25–
2.42) 
2.47 (1.92–
3.18) 
Hospitalization for heart failure 
n/N <45 28/299 79/1444 121/1200 <120 84/1016 87/1408 16/135 
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PP 
Diastolic BP subgroups Systolic 
BP 
Diastolic BP subgroups 
<70 mmHg 70–79 mmHg ≥80 mmHg <70 mmHg 70–79 mmHg ≥80 mmHg 
Event rate, % mmHg 9.4 5.5 10.1 mmHg 8.3 6.2 11.9 
HR (95% CI) 
2.07 (1.39–
3.07) 
1.40 (1.09–
1.81) 
2.52 (2.02–
3.14) 
2.12 (1.65–
2.72) 
1.47 (1.15–
1.88) 
4.67 (2.80–
7.79) 
n/N 
45–64 
mmHg 
109/1754 274/7576 444/6105 
120–139 
mmHg 
86/1618 265/7590 302/4915 
Event rate, % 6.2 3.6 7.3 5.3 3.5 6.1 
HR (95% CI) 
1.82 (1.45–
2.29) 1.00 (–) 
1.66 (1.42–
1.94) 
1.68 (1.31–
2.15) 1.00 (–) 
1.43 (1.21–
1.70) 
n/N 
≥65 
mmHg 
55/874 77/1539 118/1120 
≥140 
mmHg 
22/293 78/1561 365/3375 
Event rate, % 6.3 5.0 10.5 7.5 5.0 10.8 
HR (95% CI) 
1.89 (1.40–
2.55) 
1.41 (1.09–
1.83) 
2.63 (2.11–
3.28) 
2.38 (1.53–
3.71) 
1.45 (1.12–
1.87) 
2.60 (2.21–
3.07) 
 
Covariates at those indicated for model 1. 
BP=blood pressure; CI=confidence interval; HR=hazard ratio; PP=pulse pressure 


